Concomitant occurrence of pulmonary invasive aspergillosis and Pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma

Pancreas. 2013 Jan;42(1):178-80. doi: 10.1097/MPA.0b013e31825486f8.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Anti-Bacterial Agents / therapeutic use
  • Antifungal Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Aspergillus fumigatus / isolation & purification
  • Camptothecin / administration & dosage
  • Camptothecin / adverse effects
  • Camptothecin / analogs & derivatives
  • Fluorouracil / administration & dosage
  • Fluorouracil / adverse effects
  • Humans
  • Invasive Pulmonary Aspergillosis / chemically induced*
  • Invasive Pulmonary Aspergillosis / diagnosis
  • Invasive Pulmonary Aspergillosis / drug therapy
  • Invasive Pulmonary Aspergillosis / microbiology
  • Irinotecan
  • Male
  • Middle Aged
  • Neutropenia / chemically induced*
  • Opportunistic Infections / chemically induced*
  • Opportunistic Infections / diagnosis
  • Opportunistic Infections / drug therapy
  • Opportunistic Infections / microbiology
  • Organoplatinum Compounds / administration & dosage
  • Organoplatinum Compounds / adverse effects
  • Oxaliplatin
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / pathology
  • Pneumocystis carinii / isolation & purification
  • Pneumonia, Pneumocystis / chemically induced*
  • Pneumonia, Pneumocystis / diagnosis
  • Pneumonia, Pneumocystis / drug therapy
  • Pneumonia, Pneumocystis / microbiology
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • Organoplatinum Compounds
  • Oxaliplatin
  • Irinotecan
  • Fluorouracil
  • Camptothecin